natgillin/translations-raw huggingface dataset:
The active substances are saxagliptin and metformin hydrochloride. 
Učinkovini sta saksagliptin in metforminijev klorid.
At high doses in rats, saxagliptin caused reduced ossification (a developmental delay) of the foetal pelvis and decreased foetal body weight (in the presence of maternal toxicity), with a NOEL 303 and 30 times the human exposure for saxagliptin and the major metabolite, respectively, at RHD. 
V velikih odmerkih je saksagliptin pri podganah zmanjšal osifikacijo (razvojna upočasnitev) plodove medenice in telesno maso plodov (v prisotnosti toksičnih učinkov pri samicahmaterah); NOEL je bila 303-kratnik človeške izpostavljenosti saksagliptinu in 30-kratnik človeške izpostavljenosti njegovemu glavnemu presnovku pri RHD.
(uncommon), and erectile dysfunction (uncommon). 
in erektilna disfunkcija (občasno).
• being sick or indigestion (dyspepsia) 
• siljenje na bruhanje ali težave z želodcem (dispepsija)
What Komboglyze contains 
Kaj vsebuje zdravilo Komboglyze
The incidence of hypersensitivity reactions was 1.1% in both saxagliptin-treated patients and placebotreated patients. 
Incidenca preobčutljivostnih reakcij je bila 1,1 % tako pri bolnikih, ki so prejemali saksagliptin, kot pri tistih, ki so prejemali placebo.
Glycaemic control should be carefully assessed when saxagliptin is used concomitantly with a potent CYP3A4 inducer. 
V primeru uporabe saksagliptina sočasno z močnim induktorjem CYP3A4 je treba natančno kontrolirati urejenost glikemije.
Ulcerative and necrotic skin lesions have been reported in extremities of monkeys in non-clinical toxicology studies for saxagliptin (see section 5.3). 
V predkliničnih toksikoloških študijah saksagliptina so bile zabeležene ulcerativne in nekrotične kožne spremembe na okončinah opic (glejte poglavje 5.3).
Metformin may act via three mechanisms: - by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in muscle; - by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation; - by delaying intestinal glucose absorption. 
Metformin lahko deluje preko treh mehanizmov: - z zavrtjem glukoneogeneze in glikogenolize v mišicah zmanjšuje nastajanje glukoze v jetrih.
After an oral dose of metformin, tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects. 
Absolutna biološka uporabnost tablete 500 mg metformina je pri zdravih preiskovancih približno 50-60 %.
Nervous system disorders Metallic taste 
Bolezni živčevja kovinski okus pogosti
The reductions from baseline in HbA1c respectively for saxagliptin and sitagliptin in the primary per-protocol analysis were -0.5% (mean and median) and -0.6% (mean and median). 
V primarni analizi po protokolu se je HbA1c v primerjavi z izhodiščem s saksagliptinom znižal za -0,5 % (povprečje in mediana) in s sitagliptinom za -0,6 % (povprečje in mediana).
A 3-month dog study and embryo-foetal development studies in rats and rabbits have been conducted with the combination of saxagliptin and metformin. 
S kombinacijo saksagliptina in metformina so bile izvedene 3-mesečna študija pri psih in študije embriofetalnega razvoja pri podganah in kuncih.
There was a numerical imbalance in non-CV death, with more events on saxagliptin (1.8%) than placebo (1.4%) [HR = 1.27; (95% CI 1.00, 1.62); P = 0.051]. 
Obstajalo je številsko neravnovesje smrti zaradi drugih vzrokov, kot so srčno-žilni, in sicer z več dogodki v skupini s saksagliptinom (1,8 %) kot v skupini s placebom (1,4 %) [razmerje ogroženosti 1,27, (95 % IZ: 1,00, 1,62), p = 0,051].
Saxagliptin add-on combination therapy with insulin (with or without metformin) A total of 455 patients with type 2 diabetes participated in a 24-week randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of saxagliptin in combination with a stable dose of insulin (baseline mean: 54.2 Units) in patients with inadequate glycaemic control (HbA1c ≥ 7.5% and ≤ 11%) on insulin alone (n=141) or on insulin in combination with a stable dose of metformin (n=314). 
Saksagliptin kot dodatek zdravljenju z insulinom (z ali brez metformina) V 24-tedenski, randomizirani, dvojno-slepi, s placebom kontrolirani študiji je sodelovalo 455 bolnikov s sladkorno boleznijo tipa 2 z namenom oceniti učinkovitost in varnost saksagliptina v kombinaciji s stabilnim odmerkom insulina (povprečno izhodišče: 54,2 enoti) pri bolnikih z neustrezno urejeno glikemijo (HbA1c ≥ 7.5 % in ≤ 11 %) z zgolj insulinom (n = 141) ali z insulinom v kombinaciji s stabilnim odmerkom metformina (n = 314).
Do not take this medicine if you are breast-feeding or plan to breast-feed. 
Ne jemljite tega zdravila, če dojite ali nameravate dojiti.
Mean HbA1c change is the difference between the saxagliptin 5 mg + metformin and metformin alone groups. 
Povprečna sprememba HbA1c je razlika med skupinama s kombinacijo 5 mg saksagliptina in metforminom ter z metforminom samim.
Postmarketing reports of rash have been described in the DPP4 inhibitor class. 
V skupini zaviralcev DPP4 je bil med postmarketinškim obdobjem opisan izpuščaj.
Saxagliptin (n=186) provided significant improvements in HbA1c, FPG, and PPG compared to placebo (n=175). 
Saksagliptin (n = 186) je HbA1c, glukozo v plazmi na tešče in postprandialno glukozo izboljšal značilno bolj kot placebo (n = 175).
The incidence of adjudicated pancreatitis events was 0.3% in both saxagliptin-treated patients and placebo-treated patients in the intent-to-treat population. 
Incidenca presojenih pankreatitičnih dogodkov je bila v populaciji z namenom zdravljenja 0,3 % tako med bolniki, ki so prejemali saksagliptin, kot med tistimi, ki so prejemali placebo.
Saxagliptin add-on to metformin compared with sulphonylurea add-on to metformin A 52-week study was conducted to evaluate the efficacy and safety of saxagliptin 5 mg in combination with metformin (428 patients) compared with sulphonylurea (glipizide, 5 mg titrated as needed to 20 mg, mean dose of 15 mg) in combination with metformin (430 patients) in 858 patients with inadequate glycaemic control (HbA1c 6.5-10%) on metformin alone. 
Dodatek saksagliptina metforminu v primerjavi z dodatkom sulfonilsečnine metforminu Opravljena je bila 52-tedenska študija za oceno učinkovitosti in varnosti 5 mg saksagliptina v kombinaciji z metforminom (428 bolnikov) v primerjavi s sulfonilsečnino (glipizid, 5 mg s prilagajanjem po potrebi do 20 mg, povprečni odmerek 15 mg) v kombinaciji z metforminom (430 bolnikov) pri 858 bolnikih, ki so imeli med prejemanjem samega metformina neustrezno urejeno glikemijo (HbA1c 6,5-10 %).
Immunocompromised patients, such as patients who have undergone organ transplantation or patients diagnosed with human immunodeficiency syndrome, have not been studied in the saxagliptin clinical program. 
V kliničnem programu saksagliptina niso bili raziskani imunsko oslabeli bolniki, npr. bolniki po presaditvi organa ali bolniki z ugotovljenim sindromom humane imunske pomanjkljivosti.
BLISTERS (PERFORATED/NON-PERFORATED) for Komboglyze 2.5 mg/850 mg tablets 
PRETISNI OMOTI (PERFORIRANI/NEPERFORIRANI) Komboglyze 2,5 mg/850 mg tablete
Symptoms of a serious allergic reaction may include: - Rash - Raised red patches on your skin (hives) 
izpuščaj izbočene rdeče lise na vaši koži (koprivnico)
Maximum total daily dose is 5 mg. 
Največji celotni dnevni odmerek je 5 mg.
In subjects with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment the exposures to saxagliptin were 1.1-, 1.4- and 1.8-fold higher, respectively, and the exposures to BMS-510849 were 22%, 7%, and 33% lower, respectively, than those observed in healthy subjects. 
V primerjavi z zdravimi osebami je bila pri bolnikih z blago okvaro jeter (stopnja A po Child-Pughu) izpostavljenost saksagliptinu 1,1-krat večja in izpostavljenost BMS-510849 22 % manjša, z zmerno okvaro jeter (stopnja B po Child-Pughu) 1,4-krat večja oz. 7 % manjša ter s hudo okvaro jeter (stopnja C po Child-Pughu) 1,8-krat večja oz. 33 % manjša.
The reduction in FPG was slightly less in the saxagliptin group and there were more discontinuations (3.5% vs. 1.2%) due to lack of efficacy based on FPG criteria during the first 24 weeks of the study. 
Zmanjšanje glukoze v plazmi na tešče je bilo v skupini s saksagliptinom nekoliko manjše in v prvih 24 tednih študije so zabeležili več prekinitev zdravljenja (3,5 % v prim.
One component of the secondary composite endpoint, hospitalisation for heart failure, occurred at a greater rate in the saxagliptin group (3.5%) compared with the placebo group (2.8%), with nominal statistical significance favouring placebo [HR=1.27; (95% CI 1.07, 1.51); P=0.007]. 
Delež enega elementa sekundarnega sestavljenega opazovanega dogodka, sprejemov v bolnišnico zaradi srčnega popuščanja, je bil v skupini s saksagliptinom večji (3,5 %) kot v skupini s placebom (2,8 %); nominalna statistična značilnost je bila v korist placeba [razmerje ogroženosti = 1,27, (95 % IZ 1,07, 1,51), p = 0,007].
Hospitalisation for heart failure, occurred at a greater rate in the saxagliptin group (3.5%) compared with the placebo group (2.8%), with nominal statistical significance favouring placebo [HR = 1.27; 95% CI 1.07, 1.51); P = 0.007]. 
Delež sprejemov v bolnišnico zaradi srčnega popuščanja je bil v skupini s saksagliptinom večji (3,5 %) kot v skupini s placebom (2,8 %); nominalna statistična značilnost je bila v korist placeba [razmerje ogroženosti = 1,27, (95 % IZ 1,07, 1,51), p = 0,007].
Improvements in HbA1c, PPG, and FPG following initial therapy with saxagliptin 5 mg plus metformin were sustained up to Week 76. 
Izboljšanja HbA1c, postprandialne glukoze in glukoze v plazmi na tešče so se po uvodnem zdravljenju s 5 mg saksagliptina v kombinaciji z metforminom ohranila do 76. tedna.
BLISTERS (PERFORATED/NON-PERFORATED) for Komboglyze 2.5 mg/1,000 mg tablets 
PRETISNI OMOTI (PERFORIRANI/NEPERFORIRANI) Komboglyze 2,5 mg/1000 mg tablete
Saxagliptin add-on combination therapy with metformin and sulphonylurea A total of 257 patients with type 2 diabetes participated in a 24-week randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of saxagliptin (5 mg once daily) in combination with metformin plus sulphonylurea (SU) in patients with inadequate glycaemic control (HbA1c ≥ 7% and ≤ 10%). 
Dodatek saksagliptina kombiniranemu zdravljenju z metforminom in sulfonilsečnino Skupno 257 bolnikov s sladkorno boleznijo tipa 2 je sodelovalo v 24-tedenski randomizirani, dvojno slepi, s placebom kontrolirani študiji za oceno učinkovitosti in varnosti saksagliptina (5 mg enkrat na dan) v kombinaciji z metforminom in sulfonilsečnino (SU - sulphonylurea) pri bolnikih z nezadostno urejeno glikemijo (HbA1c ≥ 7 % in ≤ 10 %).
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic medicinal products that are eliminated by renal tubular secretion are co-administered. 
V primeru sočasne uporabe kationskih zdravil, ki se izločajo z ledvično tubulno sekrecijo, je zato treba natančno kontrolirati urejenost glikemije, odmerek prilagoditi v okviru priporočenega odmerjanja in razmisliti o spremembah zdravljenja sladkorne bolezni.
For patients inadequately controlled on dual combination therapy of a sulphonylurea and metformin, or for patients switching from triple combination therapy of saxagliptin, metformin and a sulphonylurea taken as separate tablets 
Za bolnike, neustrezno urejene na dvotirnem zdravljenju s sulfonilsečnino in metforminom, ali za bolnike, ki prehajajo s tritirnega kombiniranega zdravljenja s saksagliptinom, metforminom in sulfonilsečnino v ločenih tabletah
Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of Komboglyze in patients with GFR < 60 mL/min. 
Pri bolnikih z GFR < 60 ml/min je treba pred uvedbo zdravila Komboglyze pregledati dejavnike, ki lahko povečajo tveganje za laktacidozo (glejte poglavje 4.4).
The HbA1c change for saxagliptin 5 mg plus metformin (n=177) compared to metformin plus placebo (n=147) was -0.5% at Week 76. 
Po 76 tednih je bila sprememba HbA1c s 5 mg saksagliptina in metforminom (n = 177) v primerjavi z metforminom in placebom (n = 147) -0,5 %.
Mean change from baseline HbA1c (%) 
Povprečni izhodiščni HbA1c (%)
Komboglyze 2.5 mg/850 mg film-coated tablets Komboglyze 2.5 mg/1,000 mg film-coated tablets 
Komboglyze 2,5 mg/850 mg filmsko obložene tablete Komboglyze 2,5 mg/1000 mg filmsko obložene tablete
Komboglyze 2.5 mg/850 mg film-coated tablets Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 850 mg of metformin hydrochloride. 
Komboglyze 2,5 mg/850 mg filmsko obložene tablete Ena tableta vsebuje 2,5 mg saksagliptina (v obliki klorida) in 850 mg metforminijevega klorida.
• Komboglyze 2.5 mg/850 mg film-coated tablets (‘tablets') are light brown to brown and round, with “2.5/850” printed on one side and “4246” printed on the other side, in blue ink. 
• Zdravilo Komboglyze 2,5 mg/850 mg filmsko obložene tablete (»tablete«) so svetlo rjave do rjave okrogle tablete, ki imajo z modrim črnilom na eni strani natisnjeno oznako "2.5/850" in na drugi strani oznako "4246".
Komboglyze 2.5 mg/1,000 mg film-coated tablets Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 1,000 mg of metformin hydrochloride. 
Komboglyze 2,5 mg/1000 mg filmsko obložene tablete Ena tableta vsebuje 2,5 mg saksagliptina (v obliki klorida) in 1000 mg metforminijevega klorida.
Saxagliptin add-on to dapagliflozin plus metformin therapy A 24-week randomised, double-blind, placebo-controlled study conducted in patients with type 2 diabetes mellitus compared saxagliptin 5 mg with placebo as add-on therapy in individuals with HbA1c 7-10.5% treated with dapagliflozin (SGLT2-inhibtor) and metformin. 
Dodatek saksagliptina zdravljenju s kombinacijo dapagliflozin + metformin 24-tedenska randomizirana, dvojno slepa, s placebom kontrolirana študija pri bolnikih s sladkorno boleznijo tipa 2 je primerjala 5 mg saksagliptina in placebo kot dodatek zdravljenju pri bolnikih, ki so imeli med zdravljenjem z dapagliflozinom (zaviralec SGLT2) in metforminom HbA1c od 7 do 10,5 %.
Saxagliptin in combination with metformin as initial therapy A 24-week study was conducted to evaluate the efficacy and safety of saxagliptin 5 mg in combination with metformin as initial combination therapy in treatment-naive patients with inadequate glycaemic control (HbA1c 8-12%). 
Saksagliptin v kombinaciji z metforminom kot uvodno zdravljenje Opravljena je bila 24-tedenska študija za oceno učinkovitosti in varnosti 5 mg saksagliptina v kombinaciji z metforminom kot uvodnim kombiniranim zdravljenjem pri bolnikih, ki še niso dobivali zdravil in so imeli nezadostno urejeno glikemijo (HbA1c 8-12 %).
From a baseline mean absolute lymphocyte count of approximately 2,200 cells/μL, a mean decrease of approximately 100 cells/μL relative to placebo was observed in the placebo-controlled pooled analysis. 
V kumulativni analizi podatkov, kontroliranih s placebom, so v primerjavi s placebom ugotovili povprečno zmanjšanje absolutnega števila limfocitov za približno 100 celic/μl glede na izhodiščno povprečno absolutno število limfocitov, približno 2.200 celic/μl.
Mean HbA1c change is the difference between the saxagliptin 5 mg + metformin and metformin alone groups (p< 0.0001). 
Povprečna sprememba HbA1c je razlika med skupinama s kombinacijo 5 mg saksagliptina in metforminom ter z metforminom samim (p < 0,0001).
The HbA1c change for saxagliptin 5 mg plus metformin (n=31) compared to placebo plus metformin (n=15) was -0.8% at Week 102. 
Po 102 tednih je bila sprememba HbA1c s 5 mg saksagliptina in metforminom (n = 31) v primerjavi s placebom in metforminom (n = 15) -0,8 %.
• Komboglyze 2.5 mg/1,000 mg film-coated tablets (‘tablets') are pale yellow to light yellow and oval, with “2.5/1000” printed on one side and “4247” printed on the other side, in blue ink. 
• Zdravilo Komboglyze 2,5 mg/1000 mg filmsko obložene tablete (»tablete«) so bledorumene do svetlo rumene ovalne tablete, ki imajo z modrim črnilom na eni strani natisnjeno oznako "2.5/1000" in na drugi strani oznako "4247".
For patients inadequately controlled on dual combination therapy of dapagliflozin and metformin, or for patients switching from triple combination therapy of saxagliptin, metformin and dapagliflozin taken as separate tablets 
Za bolnike, neustrezno urejene na dvotirnem zdravljenju z dapagliflozinom in metforminom, ali za bolnike, ki prehajajo s tritirnega kombiniranega zdravljenja s saksagliptinom, metforminom in dapagliflozinom v ločenih tabletah
A 3-month dog study was conducted with the combination of saxagliptin and metformin. 
S kombinacijo saksagliptina in metformina je bila opravljena 3-mesečna študija pri psih.
n=Randomised patients 
n = randomizirani bolniki (primarna analiza učinkovitosti z-namenom-zdravljenja).
Table 4 presents adverse reactions by system organ class and by frequency category. 
Podatki iz kliničnih preskušanj in obdobja trženja Preglednica 4 prikazuje neželene učinke po organskih sistemih in kategoriji pogostnosti.
In a pooled analysis, of 1,681 patients with type 2 diabetes including 882 patients treated with saxagliptin 5 mg, randomised in five double-blind, placebo-controlled clinical safety and efficacy studies conducted to evaluate the effects of saxagliptin on glycaemic control, the overall incidence of AEs in patients treated with saxagliptin 5 mg was similar to placebo. 
Kumulativna analiza petih dvojno slepih, s placebom kontroliranih kliničnih študij varnosti in učinkovitosti, narejenih za ovrednotenje vpliva saksagliptina na urejenost glikemije, je zajela 1.681 bolnikov s sladkorno boleznijo tipa 2, vključno z 882 bolniki, ki so prejemali 5 mg saksagliptina.
Titanium dioxide (E171) Talc (E553b) 
titanov dioksid (E171) smukec (E553b) rdeči železov oksid (E172) rumeni železov oksid (E172)
No appreciable accumulation of either saxagliptin or its major metabolite was observed with repeated once-daily dosing at any dose level. 
Med večkratnim odmerjanjem enkrat na dan pri nobenem od odmerkov ni prišlo do upoštevanja vrednega kopičenja saksagliptina ali njegovega glavnega presnovka.
For patients inadequately controlled on dual combination therapy of insulin and metformin, or for patients controlled on triple combination therapy of insulin, and metformin plus saxagliptin as separate tablets 
Bolniki, ki so nezadostno urejeni z dvotirnim kombiniranim zdravljenjem z insulinom in metforminom ali bolniki, ki uporabljajo tritirno kombinirano zdravljenje z insulinom ter metforminom in saksagliptinom v ločenih tabletah
The proportion of patients achieving HbA1c < 7% at Week 24 was higher in the saxagliptin 5 mg plus dapagliflozin plus metformin group 35.3% (95% CI [28.2, 42.4]) compared to the placebo plus dapagliflozin plus metformin group 23.1% (95% CI [16.9, 29.3]). 
Delež bolnikov, ki so po 24 tednih dosegli HbA1c < 7,0 %, je bil v skupini, ki je prejemala kombinacijo 5 mg saksagliptina ter dapagliflozina in metformina, večji (35,3 %; 95 % IZ: 28,2, 42,4)
Improvements in HbA1c, PPG, and FPG following treatment with saxagliptin 5 mg plus metformin were sustained up to Week 102. 
Izboljšanja HbA1c, postprandialne glukoze in glukoze v plazmi na tešče so se ohranila do 102. tedna po zdravljenju s 5 mg saksagliptina v kombinaciji z metforminom.
Rash has been seen with saxagliptin and with certain anti-diabetic medicines in the same class as saxagliptin. 
Med uporabo saksagliptina in nekaterih zdravil za zdravljenje sladkorne bolezni, ki spadajo v isto skupino kot saksagliptin, so opažali izpuščaj.
To control your diabetes, you still need to diet and exercise, even when you are taking this medicine. 
Tudi če jemljete to zdravilo, morate za obvladovanje sladkorne bolezni še vedno upoštevati dieto in biti telesno dejavni.
System organ class Adverse Reaction 
Organski sistem Neželeni učinek
How to store Komboglyze 
Shranjevanje zdravila Komboglyze
Saxa 2.5 mg twice daily add-on to metformin; Study CV181080 (n=74) Add-on/combination studies with additional therapies Add-on to insulin (+/- metformin) Saxa 5 mg daily, Study CV181057: 
12 tednov saksagliptin 2.5 mg dvakrat dnevno kot dodatek metforminu; študija CV181080 (n = 74)
If you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see “Risk of lactic acidosis” below) or ketoacidosis. 
Če se pri vas pojavijo omenjeni simptomi, prenehajte jemati to zdravilo in takoj obvestite zdravnika ali medicinsko sestro; če ste kdaj imeli diabetično komo; če imate nenadzorovano sladkorno bolezen, na primer s hudo hiperglikemijo (visoko ravnjo sladkorja v krvi), siljenjem na bruhanje, bruhanjem, drisko, hitro izgubo telesne mase, laktacidozo (glejte spodaj "Tveganje za laktacidozo") ali ketoacidozo.
Each film-coated tablet contains 2.5 mg saxagliptin (as hydrochloride) and 850 mg metformin hydrochloride. 
Ena filmsko obložena tableta vsebuje 2,5 mg saksagliptina (v obliki klorida) in 850 mg metforminijevega klorida.
There were 4,148 patients with type 2 diabetes, including 3,021 patients treated with saxagliptin, randomised in six double-blind, controlled clinical safety and efficacy studies conducted to evaluate the effects of saxagliptin on glycaemic control. 
V šest dvojno slepih kontroliranih kliničnih študij varnosti in učinkovitosti, narejenih za ovrednotenje učinkov saksagliptina na urejenost glikemije, je bilo randomiziranih 4.148 bolnikov s sladkorno boleznijo tipa 2, vključno s 3.021 bolniki, zdravljenimi s saksagliptinom.
An add-on to metformin placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with metformin in patients with inadequate glycaemic control (HbA1c 7-10%) on metformin alone. 
Saksagliptin kot dodatek k zdravljenju z metforminom Opravljena je bila 24-tedenska, s placebom kontrolirana, študija dodatka k metforminu za oceno učinkovitosti in varnosti saksagliptina v kombinaciji z metforminom pri bolnikih, ki s samim metforminom glikemije niso imeli dovolj urejene (HbA1c od 7-10 % ).
In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite, were meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or famotidine. 
Metformin, glibenklamid, pioglitazon, digoksin, simvastatin, omeprazol, antacidi in famotidin v študijah pri zdravih prostovoljcih niso bistveno spremenili farmakokinetike saksagliptina niti njegovega glavnega presnovka.
Saxagliptin has been shown to be well-tolerated with no clinically meaningful effect on QTc interval or heart rate at oral doses up to 400 mg daily for 2 weeks (80 times the recommended dose). 
Ugotovljeno je, da saksagliptin v peroralnih odmerkih do 400 mg na dan 2 tedna (to je 80-kratnik priporočenega odmerka) bolniki dobro prenašajo ter ne vpliva klinično pomembno na interval QTc ali srčno frekvenco.
Each film-coated tablet contains 2.5 mg saxagliptin (as hydrochloride) and 1,000 mg metformin hydrochloride. 
Ena filmsko obložena tableta vsebuje 2,5 mg saksagliptina (v obliki klorida) in 1000 mg metforminijevega klorida.
Symptoms can include, but are not limited to, increasing shortness of breath, rapid increase in weight and swelling of the feet (pedal oedema); 
Med simptomi so lahko kratka sapa, hiter porast telesne mase in oteklost stopal, lahko pa se pojavijo še drugi simptomi.
Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 850 mg of metformin hydrochloride. 
Ena tableta vsebuje 2,5 mg saksagliptina (v obliki klorida) in 850 mg metforminijevega klorida.
Pale yellow to light yellow, biconvex, oval shaped, film-coated tablets, with “2.5/1000” printed on one side and “4247” printed on the other side, in blue ink. 
Komboglyze 2,5 mg/1000 mg filmsko obložene tablete Bledorumene do svetlo rumene, bikonveksne, filmsko obložene tablete, ovalne oblike, ki imajo z modrim črnilom na eni strani natisnjeno oznako "2.5/1000" in na drugi strani oznako "4247".
CARTON Komboglyze 2.5 mg/850 mg film-coated tablets 
ŠKATLA Komboglyze 2,5 mg/850 mg filmsko obložene tablete